Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Strengthening the Medical Error "Meme Pool".

Mazer BL, Nabhan C.

J Gen Intern Med. 2019 Oct;34(10):2264-2267. doi: 10.1007/s11606-019-05156-7. Epub 2019 Jul 10.

PMID:
31292902
2.

Surrogate End Points and Patient-Reported Outcomes for Novel Oncology Drugs Approved Between 2011 and 2017.

Zettler M, Basch E, Nabhan C.

JAMA Oncol. 2019 Jul 3. doi: 10.1001/jamaoncol.2019.1760. [Epub ahead of print] No abstract available.

PMID:
31268471
3.

Gone too soon: Remembering Arti Hurria.

Nabhan C.

J Geriatr Oncol. 2019 May 23. pii: S1879-4068(19)30095-5. doi: 10.1016/j.jgo.2019.05.006. [Epub ahead of print] No abstract available.

PMID:
31130441
4.

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP.

Blood Adv. 2019 May 28;3(10):1568-1573. doi: 10.1182/bloodadvances.2019000180.

5.

Real-world Evidence-What Does It Really Mean?

Nabhan C, Klink A, Prasad V.

JAMA Oncol. 2019 Jun 1;5(6):781-783. doi: 10.1001/jamaoncol.2019.0450. No abstract available.

PMID:
31095259
6.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR.

Clin Cancer Res. 2019 Jul 15;25(14):4264-4270. doi: 10.1158/1078-0432.CCR-19-0361. Epub 2019 Apr 19.

PMID:
31004001
7.

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Chen B, Nagai S, Armitage JO, Witherspoon B, Nabhan C, Godwin AC, Yang YT, Kommalapati A, Tella SH, DeAngelis C, Raisch DW, Sartor O, Hrushesky WJ, Ray PS, Yarnold PR, Love BL, Norris LB, Knopf K, Bobolts L, Riente J, Luminari S, Kane RC, Hoque S, Bennett CL.

Oncologist. 2019 Apr;24(4):537-548. doi: 10.1634/theoncologist.2018-0341. Epub 2019 Mar 6.

8.

Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.

Godfrey JK, Nabhan C, Karrison T, Kline JP, Cohen KS, Bishop MR, Stadler WM, Karmali R, Venugopal P, Rapoport AP, Smith SM.

Cancer. 2019 Jun 1;125(11):1830-1836. doi: 10.1002/cncr.31877. Epub 2019 Feb 1.

PMID:
30707764
9.

The gamification of healthcare: emergence of the digital practitioner?

Phillips EG Jr, Nabhan C, Feinberg BA.

Am J Manag Care. 2019 Jan;25(1):13-15.

10.

Value in Oncology: It Is in the Eyes of the Beholder.

Nabhan C, Phillips EG, Feinberg BA.

J Natl Compr Canc Netw. 2019 Jan;17(1):2-5. doi: 10.6004/jnccn.2018.7092. No abstract available.

PMID:
30659123
11.

Orphan Cancer Drugs in the Era of Precision Medicine.

Nabhan C, Phillips EG Jr, Feinberg BA.

JAMA Oncol. 2018 Nov 1;4(11):1481-1482. doi: 10.1001/jamaoncol.2018.3498. No abstract available.

PMID:
30422250
12.

Acute myeloid leukemia in the elderly: what constitutes treatment value?

Nabhan C, Kamat S, Karl Kish J.

Leuk Lymphoma. 2019 May;60(5):1164-1170. doi: 10.1080/10428194.2018.1520992. Epub 2018 Nov 8.

PMID:
30407103
13.

How Pharmacy Benefit Managers Add to Financial Toxicity: The Copay Accumulator Program.

Nabhan C, Phillips EG Jr, Feinberg BA.

JAMA Oncol. 2018 Dec 1;4(12):1665-1666. doi: 10.1001/jamaoncol.2018.4554. No abstract available.

PMID:
30286215
14.

Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.

Jain N, Thompson P, Ferrajoli A, Nabhan C, Mato AR, O'Brien S.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:580-591. doi: 10.1200/EDBK_200691. Review.

15.

Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.

Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.

Am J Hematol. 2018 Nov;93(11):1394-1401. doi: 10.1002/ajh.25261. Epub 2018 Sep 26.

16.

Barriers to Oncology Biosimilars Uptake in the United States.

Nabhan C, Valley A, Feinberg BA.

Oncologist. 2018 Nov;23(11):1261-1265. doi: 10.1634/theoncologist.2018-0066. Epub 2018 Jul 26.

17.

Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.

Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C.

Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.

18.

Biosimilars.

Parsad S, Nabhan C.

JAMA Oncol. 2018 Jul 1;4(7):1023. doi: 10.1001/jamaoncol.2018.0999. No abstract available.

PMID:
29879276
19.

Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research.

Feinberg BA, Bharmal M, Klink AJ, Nabhan C, Phatak H.

Future Oncol. 2018 Nov;14(27):2841-2848. doi: 10.2217/fon-2018-0317. Epub 2018 May 31.

PMID:
29848070
20.

Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016.

Zettler M, Nabhan C.

JAMA Oncol. 2018 Jul 1;4(7):993-994. doi: 10.1001/jamaoncol.2018.0610. No abstract available.

21.

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C.

J Geriatr Oncol. 2018 Jul;9(4):321-328. doi: 10.1016/j.jgo.2018.03.018. Epub 2018 Apr 17.

22.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ.

J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28.

23.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS.

Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.

24.

Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect® CLL cohort study.

Flowers CR, Nabhan C, Kay NE, Mato A, Lamanna N, Farber CM, Davids MS, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP.

Leuk Lymphoma. 2018 Oct;59(10):2327-2335. doi: 10.1080/10428194.2018.1427860. Epub 2018 Feb 7.

PMID:
29415595
25.

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence In Situ Hybridization/Cytogenetics: A Real-world Clinical Experience in the Connect CLL Registry.

Mato A, Nabhan C, Kay NE, Lamanna N, Kipps TJ, Grinblatt DL, Flowers CR, Farber CM, Davids MS, Kiselev P, Swern AS, Bhushan S, Sullivan K, Flick ED, Sharman JP.

Clin Lymphoma Myeloma Leuk. 2018 Feb;18(2):114-124.e2. doi: 10.1016/j.clml.2017.11.010. Epub 2017 Dec 6.

26.

Two Doctors, One Patient, and a Common Goal.

Nabhan C, Topin J.

Oncologist. 2018 Apr;23(4):507-509. doi: 10.1634/theoncologist.2017-0554. Epub 2018 Jan 19. No abstract available.

27.

Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.

Janiga J, Kentley J, Nabhan C, Abdulla F.

Leuk Lymphoma. 2018 Mar;59(3):562-577. doi: 10.1080/10428194.2017.1347650. Epub 2018 Jan 8. Review.

PMID:
29308723
28.

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia.

Ahn IE, Farber CM, Davids MS, Grinblatt DL, Kay NE, Lamanna N, Mato A, Nabhan C, Kiselev P, Swern AS, Flick ED, Sullivan K, Sharman JP, Flowers CR.

Blood Adv. 2017 Nov 28;1(25):2433-2443. doi: 10.1182/bloodadvances.2017011262. eCollection 2017 Nov 28.

29.

Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.

Kadri S, Lee J, Fitzpatrick C, Galanina N, Sukhanova M, Venkataraman G, Sharma S, Long B, Petras K, Theissen M, Ming M, Kobzev Y, Kang W, Guo A, Wang W, Niu N, Weiner H, Thirman M, Stock W, Smith SM, Nabhan C, Segal JP, Lu P, Wang YL.

Blood Adv. 2017 May 2;1(12):715-727. doi: 10.1182/bloodadvances.2016003632. eCollection 2017 May 9.

30.

Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.

Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, Hughes M, Nabhan C, Ali N, Schuster S, Carver J.

Cancer Biol Ther. 2018 Jan 2;19(1):1-2. doi: 10.1080/15384047.2017.1394554. Epub 2017 Dec 27.

31.

Behavioral Economics and the Future of Biosimilars.

Nabhan C, Feinberg BA.

J Natl Compr Canc Netw. 2017 Dec;15(12):1449-1451. doi: 10.6004/jnccn.2017.7023. No abstract available.

PMID:
29223980
32.

Challenges, Perceptions, and Readiness of Oncology Clinicians for the MACRA Quality Payment Program.

Nabhan C, Jeune-Smith Y, Klinefelter P, Kelly RJ, Feinberg BA.

JAMA Oncol. 2018 Feb 1;4(2):252-253. doi: 10.1001/jamaoncol.2017.3773. No abstract available.

33.

MACRA in Oncology Care: Are We Ready?

Nabhan C, Tchafa A, Feinberg BA.

J Oncol Pract. 2017 Dec;13(12):777-779. doi: 10.1200/JOP.2017.025767. Epub 2017 Nov 16. No abstract available.

PMID:
29144865
34.

RAISE Act or Reduce Act?

Nabhan C.

JAMA Oncol. 2018 Jan 1;4(1):23-24. doi: 10.1001/jamaoncol.2017.3766. No abstract available.

PMID:
29098265
35.

Clinical Pathways in Oncology: Software Solutions.

Nabhan C, Feinberg BA.

JCO Clin Cancer Inform. 2017 Nov;1:1-5. doi: 10.1200/CCI.16.00061. No abstract available.

36.

Chimeric Antigen Receptor T-Cell Therapy for Chronic Lymphocytic Leukemia: A Narrative Review.

Mato AR, Thompson MC, Nabhan C, Svoboda J, Schuster SJ.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):852-856. doi: 10.1016/j.clml.2017.07.007. Epub 2017 Jul 21. Review.

PMID:
28826693
37.

Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.

Thompson M, Brander D, Nabhan C, Mato A.

JAMA Oncol. 2018 Mar 1;4(3):394-400. doi: 10.1001/jamaoncol.2017.2009. Review.

PMID:
28750119
38.

Biosimilars in Oncology in the United States: A Review.

Nabhan C, Parsad S, Mato AR, Feinberg BA.

JAMA Oncol. 2018 Feb 1;4(2):241-247. doi: 10.1001/jamaoncol.2017.2004. Review. Erratum in: JAMA Oncol. 2017 Oct 1;3(10):1431.

PMID:
28727871
39.

Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.

Malecek MK, Petrich AM, Rozell S, Chu B, Trifilio S, Galanina N, Maurer M, Farooq U, Link BK, Nowakowski GS, Nabhan C, Ayed AO.

Am J Hematol. 2017 Nov;92(11):1156-1162. doi: 10.1002/ajh.24864. Epub 2017 Aug 17.

40.

Emerging Strategies in Treating Double Hit Lymphomas.

Nabhan C, Mato AR.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):563-568. doi: 10.1016/j.clml.2017.06.017. Epub 2017 Jun 21. Review.

PMID:
28711572
41.

Value-Based Calculators in Cancer: Current State and Challenges.

Nabhan C, Feinberg BA.

J Oncol Pract. 2017 Aug;13(8):499-506. doi: 10.1200/JOP.2017.022947. Epub 2017 Jun 15. Review.

PMID:
28617618
42.

Economic Modeling of the Cost of Chronic Lymphocytic Leukemia Therapy: It Is About the Model.

Nabhan C, Mato AR.

J Clin Oncol. 2017 Jun 1;35(16):1863-1864. doi: 10.1200/JCO.2016.71.9690. Epub 2017 Mar 13. No abstract available.

PMID:
28549225
43.

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Skarbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL, Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C.

Ann Oncol. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031.

44.

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States.

Nabhan C, Mato A, Flowers CR, Grinblatt DL, Lamanna N, Weiss MA, Davids MS, Swern AS, Bhushan S, Sullivan K, Flick ED, Kiselev P, Sharman JP.

BMC Cancer. 2017 Mar 16;17(1):198. doi: 10.1186/s12885-017-3176-x.

45.

CAR-T cells: the next era in immuno-oncology.

Feinberg BA, Fillman J, Simoncini J, Nabhan C.

Am J Manag Care. 2017 Feb;23(2 Spec No.):SP48-SP52. No abstract available.

46.

Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.

Mato AR, Timlin C, Ujjani C, Skarbnik A, Howlett C, Banerjee R, Nabhan C, Schuster SJ.

Br J Haematol. 2018 Apr;181(2):259-261. doi: 10.1111/bjh.14540. Epub 2017 Feb 21. No abstract available.

PMID:
28220935
47.

Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.

Karmali R, Nabhan C, Petrich AM, Raizer J, Peace D, Lukas R, Gordon LI, Basu S, Chukkapalli V, Venugopal P.

Br J Haematol. 2017 Apr;177(1):72-79. doi: 10.1111/bjh.14522. Epub 2017 Feb 17.

PMID:
28211579
48.

Lean: Targeted Therapy for Care Delivery.

Nabhan C, Horner G, Howell MD.

J Natl Compr Canc Netw. 2017 Feb;15(2):271-274. No abstract available.

PMID:
28188193
49.

Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study.

Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS.

Hematol Oncol. 2017 Dec;35(4):528-535. doi: 10.1002/hon.2380. Epub 2017 Jan 8.

PMID:
28066928
50.

Real-world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres.

Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP.

Br J Haematol. 2016 Dec;175(5):892-903. doi: 10.1111/bjh.14332. Epub 2016 Nov 8.

Supplemental Content

Loading ...
Support Center